- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00142922
Breaking Down Barriers to Diabetes Self-Care
March 1, 2010 updated by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Performance of self-care recommendations is key to the successful treatment of diabetes.
However, many patients have difficulty adhering to diabetes self-care recommendations.
Recent results from our own studies and others have identified specific barriers to diabetes self-care.
To evaluate the efficacy of a diabetes educator-led group intervention, the Breaking Down Barriers Program, that addresses barriers and therefore leads to improved adherence to diabetes self-care recommendations, we will randomize 222 (111 type 1 and 111 type 2) diabetes patients to one of three conditions: 1) the Breaking Down Barriers Program, 2) a cholesterol attention control condition, or 3) a 'usual care' control condition.
We hypothesize that those assigned to the Breaking Down Barriers group will improve self-care behaviors and glycemic control more than those in the two control groups.
We will follow study subjects for one year to determine whether their self-care behaviors and glycemic control improved and if the improvement was maintained over time.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
222
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Joslin Diabetes Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
For Patients With Type 1 Diabetes
- Aged 18-65
- Presence of type 1 diabetes mellitus.
- 2-25 year duration.
For Patients With Type 2 Diabetes
- Aged 25-65 years
- presence of type 2 diabetes mellitus.
- 2 years since initial diagnosis.
Exclusion Criteria:
- Renal disease, microalbumin >300 ug/mg)
- Severe peripheral diabetic neuropathy and/or severe peripheral vascular disease
- Symptomatic severe autonomic neuropathy who may be at risk when increasing activity levels.
- Women who are currently pregnant
- proliferative diabetic retinopathy based on dilated eye examination within one year of study entry. Patients whose eye disease is successfully treated will be included.
- HbA1c levels less than 7.0% (normal range 4.0 - 6.0%).
- HbA1c levels greater than 14.0%
- patients who underwent intensive insulin treatment within one year
- a history of severe, unstable myocardial infarction, congestive heart failure or other severe cardiac disease, severe hypertension (systolic more than 160 mmHg or diastolic 90 mmHg) who may be at risk when mildly increasing physical activity
- a DSMIV diagnosis of eating disorders including anorexia nervosa, bulimia, and severe weight-related insulin omission.
- Patients with recent diagnosis (past 6 months) of bipolar disorder, schizophrenia, mental retardation, organic mental disorder, and alcohol or drug abuse
- Patients whose diabetes diagnosed cannot be clearly classified as type 1 or type 2.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Attended Breaking Down Barriers program
|
completed
|
Active Comparator: 2
Attention control group
|
completed
|
Active Comparator: 3
Indivdual attention control group
|
completed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
fitness
|
Self-Care Behaviors
|
Glycemic control (HbA1c)
|
Secondary Outcome Measures
Outcome Measure |
---|
Quality of life
|
Diabetes Related emaitonal distress
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Katie Weinger, EdD, Joslin Diabetes Center/Harvard Medical School
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2002
Study Completion
October 1, 2007
Study Registration Dates
First Submitted
August 31, 2005
First Submitted That Met QC Criteria
August 31, 2005
First Posted (Estimate)
September 2, 2005
Study Record Updates
Last Update Posted (Estimate)
March 2, 2010
Last Update Submitted That Met QC Criteria
March 1, 2010
Last Verified
March 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DK 60115 (completed)
- DK 60115
- CHS00-34
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Breaking Down Barriers
-
University of LeicesterUniversity Hospitals, Leicester; Loughborough University; Baker Heart and Diabetes...CompletedType 2 Diabetes MellitusUnited Kingdom
-
National Taiwan Normal UniversityDivision of Endocrinology and Metabolism, Tri-Service General HospitalCompletedCognition | Energy Balance | Metabolic Health | Physical Activity LevelTaiwan
-
Rigshospitalet, DenmarkCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.UnknownProlonged Sitting | Breaking Prolonged Sitting With Physical ActivityDenmark
-
University of BedfordshireUnknownSedentary LifestyleUnited Kingdom
-
University of OttawaRecruitingSubstance Use | Mother-Child RelationsCanada
-
University of BathMinistry of Education, TaiwanCompletedInsulin Sensitivity
-
Uskudar State HospitalCompletedGender Bias | Researcher-Subject RelationsTurkey
-
Niraj ChavanCompleted
-
USDA Grand Forks Human Nutrition Research CenterCompleted
-
University of VirginiaRecruitingResident Education, Patient Communication, Breaking Bad News to Patients Remotely, TelemedicineUnited States